15 Sep Braeburn Appoints Brian Hirsch as General Counsel
Plymouth Meeting, Pa. —September 15, 2020—Braeburn announces that it has appointed Brian Hirsch as General Counsel and Corporate Secretary.
Mr. Hirsch joins Braeburn with more than 20 years of pharmaceutical and legal experience, handling complex legal matters for both branded and generic biopharmaceutical companies. He most recently served as Senior Vice President, Global IP, and Head, North America & LATAM, Legal and Compliance at Glenmark Pharmaceuticals. Previously he was Head of US IP Litigation at Sandoz and Associate General Counsel at Teva.
“We are very pleased to welcome Brian to Braeburn’s Executive Leadership Team,” said Mike Derkacz, President and CEO of Braeburn. “Brian brings significant depth of knowledge and experience across a broad spectrum of legal, compliance, and IP issues facing biopharma companies. We look forward to his perspective and expertise as we approach the final approval date for BRIXADI™.”
Brian earned his J.D., magna cum laude, from the University of Pennsylvania where he also completed an M.A. in Philosophy. He attended the University of Michigan where he earned his B.A.
About BRIXADI (buprenorphine) Extended-Release Injection for SC Use (CIII)
BRIXADI is an extended release weekly (8mg, 16mg, 24mg, 32mg) and monthly (64 mg, 96mg, 128mg) injection used for the treatment of moderate to severe OUD. BRIXADI is tentatively approved by FDA for patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. BRIXADI will be administered only by healthcare providers in a healthcare setting and used as part of a complete treatment program that includes counseling and psychosocial support.
Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid use disorder. Our mission is to advance next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of opioid use disorder faced by patients, healthcare providers, payers, and society. For more information about Braeburn, please visit braeburnrx.com.
For additional information, please contact:
Colleen Saltmer: email@example.com